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Abstract: Mitochondria are bilayer sub-cellular organelles that are an integral part of normal cellular
physiology. They are responsible for producing the majority of a cell’s ATP, thus supplying energy
for a variety of key cellular processes, especially in the brain. Although energy production is a
key aspect of mitochondrial metabolism, its role extends far beyond energy production to cell
signaling and epigenetic regulation–functions that contribute to cellular proliferation, differentiation,
apoptosis, migration, and autophagy. Recent research on neurological disorders suggest a major
metabolic component in disease pathophysiology, and mitochondria have been shown to be in the
center of metabolic dysregulation and possibly disease manifestation. This review will discuss the
basic functions of mitochondria and how alterations in mitochondrial activity lead to neurological
disease progression.
Keywords: metabolism; mitochondria; Alzheimer’s disease; epilepsy; traumatic brain injury
1. General Mitochondrial Function
1.1. Mitochondria: Metabolic Hub of a Cell
The mitochondrion is the result of evolution from a perfect marriage of an α-proteobacterium
and a precursor of a modern eukaryotic cell, evidenced by it being the only non-nuclear sub-cellular
organelle that has its own DNA [1]. In mammals, mitochondria are passed down maternally [2]
and they are present in every cell in the body, except red blood cells [3]. Mitochondria are bilayer
organelles with an outer and inner membrane that enclose the intermembrane space and a matrix
compartment, respectively [4]. Mitochondrial DNA (mtDNA) are circular and reside within the
matrix. Furthermore, mtDNA are intron-free which make them more susceptible to mutagenesis
than nuclear DNA [5]. The mitochondrial proteome consists of over 3300 proteins and more are
being identified daily [6]. mtDNA encode for 13 proteins that are part of the electron transport
chain, which produces ATP via oxidative phosphorylation [7]. Transport of nuclear-encoded proteins
to either the matrix or the intermembrane space requires separate signals. Matrix localization
signals are located on the N-terminal of a protein and transport to the matrix requires membrane
potential and ATP hydrolysis [8]. The intermembrane translocation signal is a hydrophilic region
internal to the cell membrane that directs protein localization independent of membrane potential
or ATP hydrolysis [9,10]. The intermembrane space is home to proteins important for mitochondrial
structural integrity and multiple proteins in the BCL-2 family that control programmed cell death
or apoptosis [11,12]. The intermembrane space and mitochondrial matrix contain proteins for the
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tricarboxylic acid (TCA) cycle—the major metabolic hub for cellular homeostasis and the electron
transport chain that generates ATP from the redox gradient [13–15]. During ATP production,
mitochondria generate a large number of reactive oxygen species (ROS) that are contained within the
matrix [16]. Controlled release of ROS supports signaling events [17–19]; however, ectopic release of
ROS from the mitochondria can result in DNA, RNA, and protein damage that ultimately leads to cell
death [20,21]. Recent advances in techniques such as real-time oxygen consumption monitoring [22]
and stable isotope enriched metabolomics have revealed an enormous amount of information on
mitochondrial metabolism and its connection to cellular physiology [23,24]. These studies confirm
that mitochondrion is an extremely complex and dynamic organelle and is at the crossroads of cellular
metabolism and signaling.
1.2. Mitochondria and Energy Production
The major biochemical pathway in the matrix of a mitochondrion is the TCA cycle, shown in
Figure 1. Dr. Hans Adolf Krebs won the Nobel Prize in Physiology or Medicine in 1953 for its discovery;
hence, it is also referred to as the Krebs cycle [25]. Dr. Krebs discovered that all of the enzymes in the
TCA cycle are bi-directional in cell-free assays [25] which led to the illustration of the circular pathway
seen in biochemical textbooks. The primary role of the TCA cycle is to extract electrons from carbon
sources in the form of NADH and FADH2 and supply them to the electron transport chain (ETC) for the
production of ATP [26,27]. Cytoplasmic metabolites supply the TCA cycle to facilitate its continuous
operation and are divided into two categories: (1) the canonical oxidative pathway and (2) anaplerotic
pathways. The canonical oxidation pathway is a continuation from glycolysis, where pyruvate enters
the TCA cycle as acetyl-CoA, carried out by the enzyme pyruvate dehydrogenase (PDH), which is then
converted to citrate [27,28]. This is viewed as the major pathway to supply oxidative phosphorylation
or ATP production. The anaplerotic pathways involve metabolic enzymes such as pyruvate carboxylase
(PCB) [29], phosphoenolpyruvate carboxykinase (PEPCK) [30], malic enzyme (ME) [31], glutaminase
(GLS) [32] and glutamate dehydrogenase (GDH) [33]. While PCB, PEPCK and ME connect the
TCA cycle with glycolysis; GLS/GDH supply carbon from glutamine. Anaplerotic pathways are
bi-directional and most commonly believed to primarily maintain compartmentalized metabolite pools
between the cytosol and mitochondria but not contribute to ATP production directly [34,35]. However,
alternative studies have suggested that glutamine supports NADH production from the GLS/GDH
anaplerotic pathway equally, if not more, when compared to the canonical pathway [36,37].
Figure 1. Major pathways and metabolite exchange that take place in the mitochondria. 1: Glycolysis
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and gluconeogenesis connects to the mitochondria by phosphoenolpyruvate (PEP), pyruvate and lactate.
2: Fatty acid biosynthesis and oxidation utilize citrate and acetyl-CoA as metabolic intermediates.
3: Glutathione (GSH) is produced in the mitochondria from glutamate, which maintains cellular
redox balance. 4: Protein biosynthesis uses de novo synthesized amino acids from the mitochondria.
5 Neurotransmitter biosynthesis (proline and GABA) partially takes place in the mitochondria
then continues in the cytosol. 6: Electron Transport Chain subunits I-V make up the Oxidative
Phosphorylation pathway and are located on the inner mitochondrial membrane and use reducing
equivalents, NADH and FADH2, as electron sources. Electrons move through the subunits from I
or II to IV, which creates a proton gradient in the process. The proton gradient is used by subunit
V to generate ATP. 7: Fumarate and succinate are exported to the cytosol as enzyme co-factors.
8: 1-carbon metabolism supplies carbon for purine nucleotide biosynthesis and methylation of
proteins and DNA. 9: Aspartate (Asp) supports pyrimidine ring biosynthesis. →: Canonical
oxidative pathway. →: Anaplerotic pathway. Pyruvate dehydrogenase (PDH); pyruvate carboxylase
(PCB); phosphoenolpyruvate carboxykinase (PEPCK); malic enzyme (ME); gamma-aminobutyric
acid (GABA).
1.3. Mitochondria and Nucleotide Biosynthesis
To maintain homeostasis during proliferation, a cell needs to produce energy, nucleotides, and fatty
acids. All three biosynthetic pathways are connected to mitochondria through metabolite exchange.
Energy production mainly stems from dehydrogenase activities within the TCA cycle, as mentioned
earlier. Nucleotide biosynthesis also relies on key metabolites inside mitochondria. The two major
classes of nucleotides are pyrimidines and purines. Pyrimidine nucleotides include cytosine, thymine,
and uracil. Its structure consists of a ribose base connected to a 4-carbon diazine ring, see Figure 2.
The ribose base is produced from the pentose phosphate pathway (PPP) that takes place in the cytosol.
The biosynthesis of the diazine ring requires oxaloacetate, a TCA cycle intermediate, as a precursor.
The first enzyme of this biochemical pathway is aspartate aminotransferase (GOT) [38] and its dominant
isoform, GOT2, is primarily a mitochondrial enzyme [39]. Purine nucleotides include the key molecules
adenine and guanine crucial for DNA and RNA biosynthesis as well as other biomolecules such as
AMP, GMP, and NADH, as shown in Figure 3. Similar in structure to pyrimidines, purine nucleotides
also contain a ribose base connected to a nitrogenous base produced from the PPP. Purine rings consist
of a pyrimidine diazine fused to an imidazole ring. The 1-carbon or folate pathway donates carbon as
5-methyltetrahydrofolate (CHO-THF) to the biosynthesis of purine rings [40]. Key enzymes involved in
this metabolic pathway include serine hydroxymethyltransferase (SMHT) [41], glycine decarboxylase
(GDC) [42], and methylenetetrahydrofolate dehydrogenase (MTHFD) [43]. All three of these enzymes
have mitochondrial isoforms expressed in a wide range of tissue types, suggesting the production of
purine rings, at least in part, takes place in the mitochondria [44,45].
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Figure 2. Biochemistry of pyrimidine nucleotide synthesis. Ribose base biosynthesis comes from the
pentose phosphate pathway (PPP) in the cytosol. Mitochondrial TCA cycle metabolites oxaloacetate
and aspartate (asp) supply three out of the four carbons in the diazine ring. •: Possible cytosolic-derived
carbons, •: Possible mitochondrial-derived carbons. •: Nitrogen.
Figure 3. Biochemistry of purine nucleotide synthesis. Ribose base biosynthesis comes from pentose
phosphate pathway (PPP) in the cytosol, mitochondrial 1-carbon metabolism contributes to purine
ring biosynthesis through 5-methyltetrahydrofolate (CHO-THF). •: Possible cytosolic-derived carbons,
•: Possible mitochondrial-derived carbons.
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1.4. Mitochondria and Fatty Acid Metabolism.
Fatty acids store energy, are precursors to lipid bilayers, and function as signaling molecules.
De novo fatty acid synthesis and β-oxidation are opposing processes that either begin or end in the
mitochondria. Acetyl-CoA and citrate are two key metabolites required for fatty acid synthesis. Citrate
derived from glucose is transported out of the mitochondria and converted by ATP citrate lyase back
to acetyl-CoA, the building block of fatty acids [46,47]. While fasting, stored fats undergo lipolysis to
produce fatty acids for ATP production. During β-oxidation, free fatty acids are added to L-carnitine
and transported into the mitochondria to be broken down sequentially to acetyl-CoA, which is then fed
into the TCA cycle for ATP production [48,49]. Recent reports suggest that mitochondrial lipids such
as lipoic acid, a co-factor for mitochondrial dehydrogenase, and 3-hydroxymyristyl-ACP, a structural
component of complex I of the electron transport chain, are made de novo inside mitochondria in
yeast [50]. To our knowledge, this process has yet to be studied in mammalian systems.
1.5. Mitochondria Metabolism and Epigenetics
Epigenetic programming is the way chromatin is organized. It has been shown to dictate cell
fate [51], control the cell cycle [52], and contribute to disease pathology [53]. Post-translational
modifications that alter gene expression patterns include histone acetylation, glycosylation,
phosphorylation, and histone or DNA methylation. Histone acetylation occurs when the mitochondrial
metabolite acetyl-CoA is added to the amino group of lysine residues on a histone. Acetyl-CoA is
produced from pyruvate dehydrogenase, fatty acid oxidation, and exogenous acetate, processes that all
take place inside mitochondria [54,55]. However, the exact relation between compartmentalized
regulation of acetyl-CoA concentration to support both mitochondrial metabolism and histone
acetylation remains unclear. Acetyl-CoA is also required for the production of uridine diphosphate
N-acetyl-glucosamine (UDP-GlcNAc), a precursor for histone glycosylation [56]. The functional
consequence of histone glycosylation is relatively unknown compared to other histone modifications
but its level seems to correlate with extracellular glucose flux [57].
Levels of mitochondrial metabolic intermediates such as ATP and NAD+ can affect histone
phosphorylation and acetylation, respectively. ATP is the substrate for histone phosphorylation
by histone kinases [58] and NAD+ is a co-factor for the sirtuin family of deacetylases [59].
Mitochondria regulate NAD+ levels in two ways: first, through oxidative phosphorylation,
where NAD+/NADH cycling takes place. Second, NAD+ is a purine nucleotide whose biosynthesis
requires the serine-glycine 1-carbon metabolic pathway mentioned above. Furthermore, hydroxylase
and demethylase activities are especially sensitive to changes in α-ketoglutarate (αKG), fumarate,
and succinate concentrations. All three molecules are substrates crucial for the functioning of
dioxygenases including prolyl hydroxylases and histone lysine demethylases, which are important for
epigenetic regulation [60–62]. Germline or somatic mutations in mitochondrial enzymes that produce
abnormal amounts of succinate [63], fumarate [64], and 2-hydroxyglutarate (2HG) [65], have been
shown to have an inhibitory effect on these enzymes, leading to DNA hypermethylation-induced
epigenetic alterations.
Mitochondrial metabolism controls the epigenetic landscape by providing substrates for
acetylation, phosphorylation, and methylation of histones. The balanced supply of substrates
from mitochondria to the nucleus is an extremely complex system that is tightly regulated by
interconnected signaling pathways. Somatic mutations or altered mitochondrial metabolism by
different diseased states greatly affect histone modification and the epigenetic landscape. Detailed
mechanisms of how a cell can maintain the flow of metabolites between mitochondria and the nucleus
to support proliferation, differentiation, and autophagy are relatively unknown and form an area of
intense research.
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2. Mitochondria Dysfunction in Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive and severe
memory loss. AD is the most common form of dementia, affecting over 5.3 million people in the
United States alone [66]. The strongest risk factor for AD is age, and as the elderly population
expands, the number of individuals afflicted with this devastating disease is growing rapidly;
particularly considering that effective therapies for the disease remain elusive [66]. The AD brain
is characterized by two neuropathological hallmarks: extracellular senile plaques and intracellular
neurofibrillary tangles [67]. The plaques are formed mostly from the deposition of amyloid β (Aβ)
peptide, while neurofibrillary tangles are formed from neurofilaments and hyperphosphorylated tau
protein. A small percentage of AD cases (<5%) are caused by mutations in genes encoding for either
the amyloid β precursor protein (APP) or from mutations in genes encoding presenilin 1 or presenilin
2 (involved in the generation of amyloid beta (Aβ) from APP) [68]. These rare, autosomal dominantly
inherited cases are typically referred to as familial or early-onset AD. However, the vast majority of
AD cases occur sporadically in individuals >65 years of age and are commonly referred to as late-onset
AD (LOAD) [67]. Despite the sporadic nature of LOAD, the inheritance of several well-established
susceptibility genes significantly increases the risk of disease [69].
In addition to advanced age, various metabolic impairments predispose individuals to cognitive
dysfunction and dementia, including LOAD. For example, metabolic dysfunction as in the case of
insulin resistance and type 2 diabetes, increases the risk of dementia and shares several pathological
characteristics with AD, such as neuroinflammation, increased oxidative stress, and cerebrovascular
dysfunction [70,71]. Metabolic disorders also increase in incidence with age [72], meaning the number
of high-risk elderly individuals suffering from metabolic disorders is expanding precipitously.
The central role of metabolism in AD is likely due to the fact that normal synaptic function
requires a multitude of energy-intensive processes [73]. The first clues pointing toward a potential
metabolic component of the disease were observed nearly four decades ago, as a series of neuroimaging
studies utilizing flurodeoxyglucose positron emission tomography (FDG-PET) that showed that
the brains of individuals with AD took up less glucose compared to those of cognitively normal
controls [74–77]. Since these initial findings in the early 1980s, a multitude of additional studies
have confirmed the phenomena, and a reduction in the cerebral metabolic rate of glucose (CMRglc),
as measured by FDG-PET, is now considered one of the hallmarks of AD [78]. In fact, FDG-PET is
able to differentiate AD from other types of dementia with a high degree of specificity due to specific
regional signaling patterns [79]. Clinical AD symptoms essentially never occur without glucose
hypometabolism, the extent of which strongly correlates with the severity of clinical symptoms [80–82].
Importantly, evidence suggests that these alterations in glucose metabolism occur very early in the
neurodegenerative process [83–86], raising the possibility that metabolic dysfunction precedes, and
possibly contributes causally, to the pathophysiology of AD.
Despite these important findings, the molecular mechanisms underlying AD neurodegeneration
remain elusive. The field has been dominated by the “amyloid hypothesis”, which argues that
sequential cleavages of APP produce Aβ, initiating a cascade of neurodegeneration [87]. In this context,
mitochondrial impairments observed in AD patients are thought to be secondary effects of Aβ toxicity,
as Aβ may block mitochondrial translocation of ETC components [88–90], and impair respiratory
chain function and oxidative phosphorylation in mitochondria [91,92]. Alternatively, some evidence
points to a direct effect of mitochondria on AD neuropathology, which are either independent of Aβ
or, themselves, potentially drive the changes in APP and Aβ homeostasis.
In support of the latter, shortly after the initial reports demonstrating the reduced glucose
uptake via FDG-PET in AD patients, a series of additional PET-based studies described reductions
in oxygen consumption in AD brains [93,94]. Importantly, around this same time, several groups
began to show evidence of mitochondrial dysfunction in AD brain tissue. This included reductions in
cytochrome oxidase (COX) activity in AD patients [88], and decreases in mitochondrial enzymes such
as PDH, and other enzymes in the early part of the TCA cycle, such as isocitrate dehydrogenase and
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α-ketoglutarate dehydrogenase (αKGDH) [95,96]. Additionally, the activity of late TCA cycle enzymes
such as succinate dehydrogenase and malate dehydrogenase were increased in AD brains, and the
alterations of TCA cycle enzyme activities correlated strongly with clinical symptoms [97]. Together,
these studies may point toward TCA enzyme activity reductions, resulting in reduced cerebral glucose
metabolism, which translates to clinically relevant cognitive impairments.
While age is the primary risk factor for AD, genetic factors also strongly contribute to disease
risk (Bertram et al., 2007; Bertram et al., 2009). The strongest genetic risk factor for the more common
late-onset form of AD is APOE [98,99]. In humans, there are three major isoforms of apoE: E2, E3,
and E4 [100]. Apolipoprotein E (apoE), which is associated with circulating lipoproteins, plays several
important metabolic roles [100]. In the periphery, apoE is primarily produced by the liver, while in
the brain, apoE is primarily produced by astrocytes, and is responsible for neuronal maintenance and
repair in addition to a number of other physiological and pathological roles [101–103]. E3 is the major
isoform expressed in humans (~60% of the population), and the effects of E2 and E4 are typically
compared to those of E3 to determine the relative risk [98,104]. Importantly, the E4 isoform confers
between a 2- (heterozygous) to 15-fold (homozygous) increase in the risk of developing AD [98],
and studies suggest the E4 allele may account for up to 50% of AD in the US [99].
Interestingly, a consistent pattern of brain glucose hypometabolism, similar to that seen in AD,
has been noted in individuals with E4 [84,105]. Even non-demented, cognitively normal E4 carriers
demonstrate this pattern of glucose hypometabolism [106]. Importantly, these metabolic deficits are
present decades in advance of AD onset in E4+ and other at-risk individuals thereby lending support
to this being an inherent biological feature of E4, rather than simply a byproduct of dementia [107,108].
The metabolic impairments associated with E4 extend beyond reductions in CMRglc to also include
mitochondrial deficits described in several in vivo and in vitro models. For example, the expression
of the subunits of several mitochondrial respiratory complexes is decreased in neurons expressing
E4 compared to those expressing E3 in a mouse model of neuron-specific apoE expression [109].
Mitochondrial protein expression was also shown to be modified by APOE genotype in both the absence
and presence of an ischemic injury [110]. Consistent with a role of upregulated mitochondria-associated
endoplasmic reticulum membrane (MAM) function in AD, Tambini et al. recently showed that
E4-containing astrocyte conditioned media increased MAM activity in vitro [111]. Additionally, a series
of studies in mice show that apoE4 is cleaved by a protease in neurons to generate a toxic apoE4(1-272)
fragment with a mitochondrial targeting sequence [112]. This fragment of apoE4 has been shown to
bind to mitochondrial complexes and affect their activities [113]. Finally, an exciting new study by
Zhao et al. shows that E4 inhibits insulin-induced mitochondrial respiration in primary neurons [114].
Two studies have reported an interaction between APOE genotype and mitochondrial DNA
haplogroups in determining AD risk [115,116], and E4-associated mitochondrial deficits have also
been confirmed in human autopsy tissue. Importantly, these abnormalities appear to begin early in
life—at a point that precedes amyloid deposition. For example, post-mortem brains from young adult
APOE ε4 carriers show reduced COX [117,118]. Interestingly, these findings extend to the periphery,
as platelet mitochondria COX activity in AD subjects with E4 alleles are lower than in non-carrier AD
subjects [119].
In addition to Alzheimer’s disease, mitochondrial dysfunction has been reported in other
neurodegenerative diseases such as Huntington’s disease, Parkinson’s disease, and amyotrophic
lateral sclerosis. Mitochondrial metabolism in these diseases has been extensively reviewed
previously [120–124]; therefore, we will be focusing on other neurological disorders such as traumatic
brain injury and epilepsy for the remainder of the review.
3. Mitochondrial Disruption Following TBI
Traumatic brain injury (TBI) is a major cause of death and disability estimated to affect
approximately 1.7 million people annually in the US [125]. The cause of injury consists of a primary
insult due to acceleration and deceleration forces on neuronal structures. Following the primary injury
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phase is the secondary injury cascade. It is believed that it is the secondary injury, involving a complex
cascade of biochemical, metabolic, and molecular changes, that leads to profound malfunctioning in
cerebral cells and permanent long-term sequelae of TBI. Importantly, metabolic changes are heavily
involved in this process [126–128]. It has been proposed that it’s the neuronal hyperexcitability,
intracellular calcium concentration elevations, and mitochondrial enzymatic alterations in the
secondary cascade that ultimately lead to oxidative stress and cellular death [129–131].
The secondary injury cascade after TBI is initiated by disruptions in the membrane potential that
lead to spontaneous firing of the neuronal cells [132]. The aberrant action potentially causes the release
of numerous neurotransmitters, primarily the excitatory amino acid glutamate [133,134]. Increases in
extracellular glutamate concentrations following TBI are accompanied by a rise in lactate and a decline
in extracellular glucose [135–137], suggestive of a shift from oxidative metabolism to non-oxidative
methods such as glycolysis. Glutamate is an amino acid that is closely intertwined with mitochondrial
energy production [138]. Its biosynthesis takes place in the mitochondria, from either αKGDH by
GDH or from glutamine by GLS. Furthermore, the cytoplasmic enzyme GOT promotes the reversible
conversion of glutamate to αKGDH, a key step during nucleotide biosynthesis. The aberrant release of
glutamate could potentially alter all of the linked pathways described above. In addition, glutamate is
one of the precursors for the production of gamma-aminobutyric acid (GABA), the major inhibitory
neurotransmitter [139,140]; hence, an ectopic release of glutamate could result in the lack of GABA
production, and consequently, a lack of inhibitory responses in the brain. The interplay between
glutamate, the TCA cycle, and mitochondrial metabolism is only beginning to emerge. Due to the
complexity of the metabolic networks affected by glutamate, further metabolomic approaches are
needed to improve our understanding at a system level.
The increase in excitatory neurotransmission from increased glutamate release leads to cellular
depolarization and calcium influx into neurons via AMPA, NMDA channel, and voltage-gated
calcium channels (VGCC) [141–143], further causing energy depletion and excitotoxic-mediated
cell death [144]. As the intracellular calcium concentration increases, the mitochondria attempt
to buffer intracellular calcium by sequestering it into the matrix through mitochondrial permeability
transition pores [143,145]. Increased mitochondrial calcium levels result in mitochondrial dysfunction
in a dose-dependent manner [146–148]. Furthermore, studies have shown that increased calcium
levels have an inhibitory effect over key mitochondrial dehydrogenase enzymes such as PDH,
NAD-dependent isocitrate dehydrogenase, and αKGDH in in vitro models [149,150]. Several studies
have confirmed these findings after TBI. PDH activity has been found to be significantly reduced in
blood levels of TBI patients [151]. Similarly, in a rodent model, αKGDH activity was decreased after
TBI, while application of a αKGDH coenzyme precursor, thiamine, rescued the activity of αKGDH and
restored mitochondrial respiration [152]. Further studies are needed to confirm the effect of calcium
elevations on other mitochondrial enzymes in TBI.
In addition to the aforementioned increase in excitatory signaling and intracellular calcium,
several other factors may contribute to the energy crisis defined after TBI. HIF1α, a transcription
factor responsive to acute hypoxia, has been found to be elevated in the brains of mice after TBI
models [153,154]. Multiple studies have documented a significant role of HIF1α in elevating aquaporin
(AQP)-4 and -9 further exacerbating brain edema post-TBI [153–155]. Pharmacological inhibition
of HIF1α using 2-methoxyestradiol (2ME2) reduced brain edema, AQP-4 and -9 expression [153].
HIF1α activation also reduces glucose and glutamine flux through mitochondria in other experimental
models [156–158]; however, it has not yet been investigated whether similar metabolic changes are
also occurring post-TBI.
It has been long shown that acute mitochondrial disruption occurs following experimental
TBI [142,159]. The secondary injury cascade after TBI causes detrimental cell damage and is marked
by alterations in excitatory amino acids such as glutamate [160,161] increases in acute hypoxia [162],
and the disruption of calcium homeostasis [141]; all of which alter mitochondrial metabolism. The vital
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roles for mitochondria in cellular function and survival have resulted in increased efforts to identify
the molecular events associated with mitochondrial impairment in TBI.
4. Role of Mitochondria in Epilepsy
Epilepsy is a neurological disorder that affects approximately 1.2% of the US population [163].
It consists of abnormal, excessive, hypersynchronous discharges from a population of neurons that
disrupt normal brain function. The causes of epilepsy are multifactorial, ranging from trauma to
the brain, tumor growth, infection, malformations, or genetic abnormalities [164]. Despite the large
variability in causes, mitochondrial dysfunction is frequently involved. Mitochondrial gene mutations
frequently lead to seizures [165,166], while nuclear genes that alter mitochondrial function can also
result in epilepsy [167]. Moreover, seizure activity triggers the release of ROS, calcium influxes,
neurotransmitter imbalances that cause further alterations in mitochondrial metabolism, and neuronal
death [168–170]. Therefore, mitochondrial dysfunction can be both a cause and a consequence of
epileptic disease [171].
Research in the last few decades has highlighted numerous nuclear genes that alter mitochondrial
function, over 100 of which have been linked to epilepsy [167]. Mutations in the nuclear gene
POLG, which encodes for the catalytic subunit of mitochondrial DNA, polymerase gamma, has been
the one of the most studied [172–177]. Mutations have resulted in numerous phenotypes ranging
from generalized seizures to myopathy, hepatopathy, sensory-ataxias, and opthalmoparesis [175,178].
Iron–sulfur clusters are important for the assembly of the electron transfer complexes [179].
Disruption of multiple genes in this pathway, such as LIAS, BOLA3, and NFU1, are associated
with mitochondrial-disease-induced epilepsy [180–182]. Furthermore, mutations in mitochondrial
transporter genes SLC25A12 and SLC25A22 are another cause of epilepsy [183,184]. These are members
of the solute carrier family 25 and are both used for intracellular glutamate transport between the
mitochondria and the cytoplasm. Aberrant function of these transporters is thought to be responsible
for excessive glutamate release leading to hyperexcitability [185–187]. Additional nuclear genes that
alter mitochondrial function and have been shown to be associated with epilepsies have been listed in
Table 1.
Table 1. Nuclear genes involved in mitochondrial function associated with epilepsy.
Gene Source
Complex I Subunits Assembly factors NDUFS1, NDUFS2, NDUFS3, NDUFS4,
NDUFS6, NDUFS7, NDUFS8, NDUFV1,
NDUFA1, NDUFA11
[188–196]
Complex I Assembly Factors NDUFAF1, NDUFAF2, NDUFAF3,
NDUFAF4, NDUFAF5, NDUFAF6, AIFM1,
FOXRED1, NUBPL
[197–203]
Complex II Subunits SDHA [204]
Complex III Subunits and Assembly
Factors
UQCC2, UQCRC2, BCS1L [205–207]
Complex IV Subunits and Assembly
Factors
NDUFA4, ETHE1, APOPT1, SURF1, SCO1,
SCO2, COX10, COX15, FASTKD2, PET100
[208–216]
Complex V Subunits and Assembly
Factors
ATP5A1, ATPAF2, TMEM70 [210,217,218]
Solute Carriers SLC25A12, SLC25A22 [183,184]
Coenzyme Q10 Biosynthesis ADCK3, COQ2, COQ4, COQ6,
COQ9, PDSS2
[219–224]
ETC Cofactor Biosynthesis LIAS, BOLA3, NFU1, NFS1, TPK, HCCS [181,182,225–228]
tRNA Aminoacylation AARS2, CARS2, DARS2, EARS2, FARS2,
NARS2, RARS2, VARS2
[229–236]
Posttranslational Regulators GFM1, TSFM, PNPT1, RMND1,
TRIT1, TRNT1
[237–242]
Mitochondrial DNA Replication C10orf2, POLG [197,243]
Nucleotide Pool DGUOK, TYMP, TK, RRMB [244–246]
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The mitochondrial genome is composed of circular, double-stranded DNA containing 37 genes
which are all essential for the normal function of the mitochondrion. While mtDNA represents only
a small fraction of total human DNA, mutations in over half of the 37 mtDNA genes have been
associated with epilepsy [167]. The most frequently occurring mutations are in mitochondrial tRNA
genes that lead to the epileptic syndromes such as mitochondrial epilepsy, lactic acidosis, stroke-like
episodes (MELAS), and myoclonic epilepsy with ragged red fibers (MERRF) [252,253]. Less commonly
seen mutations involving oxidative phosphorylation complexes also can induce various epileptic
syndromes [167,254]. For example, mutations in mitochondrial genes that result in encoding proteins
forming complexes I, III, IV, and V have been noted to cause Leigh syndrome, a mitochondrial
disorder resulting in a severe, progressive, necrotizing encephalopathy [196]. While the syndrome is
characterized by motor dysfunction and intellectual regression in the first few years of life, epilepsy is
observed in 21–39% of patients [255,256].
Mitochondrial dysfunction and seizures have been found to be closely linked not only in
genetic causes of epilepsy, but are also becoming increasingly recognized in acquired epilepsy [167].
These non-genetic causes of epilepsy include physical head trauma, infectious diseases, brain tumors,
or drug intoxications [257]. Irrespective of the trigger, seizure activity significantly decreases ATP levels
in neurons, suggestive of energy depletion [258]. Studies have identified that synaptic transmission
is the largest consumer of neuronal ATP [259,260]; therefore, with the excessive neuronal firing
during seizures, it is not surprising that energy depletion occurs leading to metabolic dysfunction
even in acquired epilepsies. Other characteristics of homeostatic changes occurring after seizures
are the accumulation of intracellular calcium and ROS [261–263]. Excess ROS and Ca2+ are potent
triggers causing the opening of the mitochondrial permeability transition pore, leading to irreversible
mitochondrial swelling and cytochrome c release, subsequently triggering mitochondrial damage
and cellular death [264,265]. Due to a neuron’s lack of glycolytic capacities, the metabolic strain
post-seizure activity increases the demand for oxidative phosphorylation and is a possible trigger for
the excess ROS and Ca2+ fluctuations. Furthermore, oxidative damage can have profound effects on
neurotransmitter uptake and release, altering neuronal excitability [266] and further increasing the
likelihood of seizure activity and exacerbating neuronal energy depletion [267].
Regardless of which came first, epilepsy and mitochondrial dysfunction interact in a vicious
cycle to deplete a neurons’ energy stores, leading to extensive brain damage. Although a detailed
connection between mitochondrial dysfunction, energy metabolism, and epilepsy remains to be
elucidated, mitochondria are clearly an integral part of disease manifestation.
5. Concluding Remarks
AD, TBI, and epilepsy are just a few of the neurological diseases with mitochondrial involvement.
Metabolic dysfunction has also been documented in numerous other neurological diseases such
as stroke [268,269], glioblastomas [270], multiple sclerosis [271,272], various neurodegenerative
diseases [120–124], and even psychiatric disorders [273–275]. In this article, we have highlighted the
importance of mitochondria metabolism in cellular pathophysiology in a few of the major neurological
disorders and hope to have shed light on areas of exploration to further unravel the complexities of
mitochondrial involvement in disease states.
Mitochondrial metabolism supplies the energy demand of a cell, coordinates the balance between
catabolism and anabolism, and maintains redox homeostasis. However, knowledge gaps still remain
to elucidate detailed mechanisms that lead to the manifestation of disease. While high-resolution
techniques, such as chromatograph-based mass spectrometry metabolomics methods, have provided
an efficient way to visualize mitochondrial metabolism in different types of cancers, these methods
have not been adopted in the field of neurological research. Future research should incorporate
traditional metabolomics and stable tracer technology to map mitochondrial metabolic flux with
high-resolution, to yield vital information for the understanding of disease pathophysiology, and to
assist in the design of future therapeutic agents to treat neurological disorders.
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